Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5861812 | 0.99 | ALDH1A1 (0.41) | KDM4EALDH1A1ADRB2TSHRCYP2D6 | |
| SCHEMBL5860585 | 0.87 | ACHE (0.42) | KDM4EALDH1A1ADRB2TSHRCYP2C9 | |
| Hydrochloric Acid SCHEMBL5861744 | 0.86 | ACHE (0.41) | KDM4EALDH1A1ADRB2TSHRCYP2C9 | |
| SCHEMBL5860590 | 0.81 | KDM4E (0.39) | KDM4EALDH1A1ADRB2TSHRCYP2D6 | |
| SCHEMBL5860558 | 0.80 | AGTR2 (0.46) | ALDH1A1 | |
| SCHEMBL11730054 | 0.77 | TSHR (0.61) | KDM4EALDH1A1ADRB2TSHRCYP2D6 | |
| SCHEMBL1590241 | 0.75 | TSHR (0.59) | KDM4EALDH1A1ADRB2TSHRCYP2D6 | |
| SCHEMBL15617312 | 0.75 | TSHR (0.59) | KDM4EALDH1A1ADRB2TSHRCYP2D6 | |
| SCHEMBL27825544 | 0.74 | TSHR (0.61) | KDM4EALDH1A1ADRB2TSHRCYP2D6 | |
| SCHEMBL8334427 | 0.72 | ALDH1A1 (0.42) | ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992097-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050143318-A1 | Growth hormone secretagogues | DODGE JEFFREY A (US) | 2005-06-30 | — | — | US | disclosed |
| US-6828331-B1 | Non-peptidyl in nature and are, therefore, more metabolically stable than growth hormone, growth hormone releasing hormone, or analogs of either of these proteins | ELI LILLY AND COMPANY | 2004-12-07 | — | — | US | disclosed |
| US-20040122234-A1 | Growth Hormone secretagogues | HAUSER KENNETH LEE (US) | 2004-06-24 | — | — | US | disclosed |
| US-6639076-B1 | Such as 2-(2-amino-2-methylpropanoylamino)-n-(1-(2-oxo-1-phenyl-2-pyrrolidinylethyl -4-yl)-4-phenylbutanamide | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| US-6329342-B1 | CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2001-12-11 | — | — | US | disclosed |
| EP-1153034-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049037-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2000-08-24 | — | — | WO | disclosed |
| EP-0933365-A2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0898963-A2 | Congestive heart failure treatment | ELI LILLY AND COMPANY (US) | 1999-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143318-A1 | Growth hormone secretagogues | GHSR, GHRHR, SSTR3 | KDM4E 3442/4885ALDH1A1 4506/4885ADRB2 234/4885 |
| US-20040122234-A1 | Growth Hormone secretagogues | GHSR, GHRHR, CRH | KDM4E 3260/4885ALDH1A1 4382/4885ADRB2 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.